Skip to main content

Table 1 IQ scores of patients and controls at each time period

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

 

Number tested

Mean adjusted IQ* (SD)

Difference in

means

(95% CI)

t-test

p-value

 

Controls

   Patients

   Controls

Patients

  

FSIQ

      

   5 months

   157

   284

102.5

(14)

101.0

(15)

1.4

(-1.5 : 4.4)

   0.3

   3 years

   173

   366

104.8

(14)

97.7

(16)

7.1

(4.4 : 9.8)

   < 0.0001

   5 years

   132

   289

105.2

(15)

100.0

(16)

5.2

(1.9 : 8.5)

   0.002

VIQ

      

   5 months

   158

   287

102.0

(14)

99.6

(15)

2.3

(-0.5 : 5.2)

   0.1

   3 years

   173

   366

103.4

(15)

97.7

(15)

5.7

(3.1 : 8.4)

   < 0.0001

   5 years

   132

   289

103.2

(14)

99.6

(15)

3.6

(0.5 : 6.7)

   0.02

PIQ

      

   5 months

   160

   299

102.5

(15)

102.0

(16)

0.5

(-2.5 : 3.5)

   0.7

   3 years

   173

   368

105.5

(15)

98.2

(16)

7.3

(4.5 : 10.1)

   < 0.0001

   5 years

   132

   289

106.4

(16)

100.5

(17)

5.9

(2.5 : 9.3)

   0.0006

  1. *IQ adjusted for test by subtracting:
  2. 7.15 from each WPPSI-R full IQ
  3. 3.79 from each WPPSI-R verbal IQ.
  4. 8.74 from each WPPSI-R performance IQ.